TW201730341A - 抑制補體b因子之表現之反義寡核苷酸 - Google Patents

抑制補體b因子之表現之反義寡核苷酸 Download PDF

Info

Publication number: TW201730341A
Authority: TW; Taiwan
Prior art keywords: methylene; modified base; dna; antisense oligonucleotide; linked bicyclic
Prior art date: 2016-02-05

Application number

TW106103617A

Other languages

English (en)

Chinese (zh)

Inventor

Yoji Yamada

Kiyoshi Shimizu

Hiroto Iwai

Asana Makino

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-05

Filing date

2017-02-03

Publication date

2017-09-01

2017-02-03 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2017-09-01 Publication of TW201730341A publication Critical patent/TW201730341A/zh

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 234
239000000074 antisense oligonucleotide Substances 0.000 title claims abstract description 143
238000012230 antisense oligonucleotides Methods 0.000 title claims abstract description 143
230000000295 complement effect Effects 0.000 title claims abstract description 41
230000014509 gene expression Effects 0.000 title claims abstract description 33
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 18
208000033626 Renal failure acute Diseases 0.000 claims abstract description 18
201000011040 acute kidney failure Diseases 0.000 claims abstract description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims abstract description 13
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims abstract description 13
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims abstract description 13
206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 13
208000002780 macular degeneration Diseases 0.000 claims abstract description 13
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims abstract description 13
201000008383 nephritis Diseases 0.000 claims abstract description 11
230000037361 pathway Effects 0.000 claims abstract description 10
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
230000005856 abnormality Effects 0.000 claims abstract description 9
208000006673 asthma Diseases 0.000 claims abstract description 9
206010018372 Glomerulonephritis membranous Diseases 0.000 claims abstract description 8
208000035475 disorder Diseases 0.000 claims abstract description 8
230000001404 mediated effect Effects 0.000 claims abstract description 8
201000008350 membranous glomerulonephritis Diseases 0.000 claims abstract description 8
231100000855 membranous nephropathy Toxicity 0.000 claims abstract description 8
201000008171 proliferative glomerulonephritis Diseases 0.000 claims abstract description 8
125000003729 nucleotide group Chemical group 0.000 claims description 191
239000002773 nucleotide Substances 0.000 claims description 144
238000000034 method Methods 0.000 claims description 46
108020004707 nucleic acids Proteins 0.000 claims description 24
102000039446 nucleic acids Human genes 0.000 claims description 24
150000007523 nucleic acids Chemical class 0.000 claims description 24
230000000692 anti-sense effect Effects 0.000 claims description 15
239000003446 ligand Substances 0.000 claims description 10
206010018366 Glomerulonephritis acute Diseases 0.000 claims description 6
231100000851 acute glomerulonephritis Toxicity 0.000 claims description 6
201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 8
239000003814 drug Substances 0.000 abstract description 4
229940079593 drug Drugs 0.000 abstract description 3
230000000750 progressive effect Effects 0.000 abstract description 3
206010018364 Glomerulonephritis Diseases 0.000 abstract description 2
-1 2-(methoxy)ethoxy, 3-aminopropoxy, 2-[(N,N-dimethylamino) Oxy]ethoxy, 3-(N,N-dimethylamino)propoxy, 2-[2-(N,N-dimethylamino)ethoxy]ethoxy Chemical group 0.000 description 265
125000002619 bicyclic group Chemical group 0.000 description 261
108020004414 DNA Proteins 0.000 description 224
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 104
108091032973 (ribonucleotides)n+m Proteins 0.000 description 61
241000282414 Homo sapiens Species 0.000 description 57
108091028664 Ribonucleotide Proteins 0.000 description 54
239000002336 ribonucleotide Substances 0.000 description 54
125000002652 ribonucleotide group Chemical group 0.000 description 54
239000005547 deoxyribonucleotide Substances 0.000 description 53
125000002637 deoxyribonucleotide group Chemical group 0.000 description 53
108020004999 messenger RNA Proteins 0.000 description 49
102000003712 Complement factor B Human genes 0.000 description 37
108090000056 Complement factor B Proteins 0.000 description 37
210000004027 cell Anatomy 0.000 description 20
108020000948 Antisense Oligonucleotides Proteins 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
239000002502 liposome Substances 0.000 description 15
239000002243 precursor Substances 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
201000000596 systemic lupus erythematosus Diseases 0.000 description 12
150000002632 lipids Chemical class 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000009396 hybridization Methods 0.000 description 9
239000007788 liquid Substances 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
125000002091 cationic group Chemical group 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 8
239000000203 mixture Substances 0.000 description 8
101150021919 CFB gene Proteins 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
235000000346 sugar Nutrition 0.000 description 7
101100005959 Homo sapiens CFB gene Proteins 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
206010028417 myasthenia gravis Diseases 0.000 description 6
239000002245 particle Substances 0.000 description 6
238000013518 transcription Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
125000004429 atom Chemical group 0.000 description 5
239000000470 constituent Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
210000005260 human cell Anatomy 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000035897 transcription Effects 0.000 description 5
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
239000002131 composite material Substances 0.000 description 4
239000011246 composite particle Substances 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000523 sample Substances 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001720 carbohydrates Chemical group 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000000084 colloidal system Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000003753 real-time PCR Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101150112014 Gapdh gene Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
229920006317 cationic polymer Polymers 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
230000009368 gene silencing by RNA Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000006210 lotion Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004779 membrane envelope Anatomy 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000003495 polar organic solvent Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011607 retinol Substances 0.000 description 2
229960003471 retinol Drugs 0.000 description 2
235000020944 retinol Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000725101 Clea Species 0.000 description 1
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
102220500344 Complement factor B_R32Q_mutation Human genes 0.000 description 1
102220500347 Complement factor B_R32W_mutation Human genes 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
206010023435 Kidney small Diseases 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
239000004333 gold (food color) Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical compound NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
150000003290 ribose derivatives Chemical group 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Zoology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW106103617A 2016-02-05 2017-02-03 抑制補體b因子之表現之反義寡核苷酸 TW201730341A (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2016021128		2016-02-05

Publications (1)

Publication Number	Publication Date
TW201730341A true TW201730341A (zh)	2017-09-01

Family

ID=59499604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW106103617A TW201730341A (zh)	2016-02-05	2017-02-03	抑制補體b因子之表現之反義寡核苷酸

Country Status (2)

Country	Link
TW (1)	TW201730341A (fr)
WO (1)	WO2017135397A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018117253A1 (fr) *	2016-12-23	2018-06-28	協和発酵キリン株式会社	Acide nucléique inhibant l'expression du facteur b du complément
WO2019027015A1 (fr) *	2017-08-02	2019-02-07	協和発酵キリン株式会社	Complexe d'acide nucléique
CN114144525B (zh) *	2019-07-24	2024-11-12	国立大学法人东北大学	嵌合分子、药物组合物、靶核酸的切割方法以及靶核酸切割用或诊断用试剂盒
CN110951915A (zh) *	2019-11-21	2020-04-03	南方医科大学南方医院	一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒
MX2023006714A (es) *	2020-12-08	2023-07-13	Univ Fukuoka	Acido ribonucleico (arn) guia estable de edicion de objetivo al cual se introduce acido nucleico quimicamente modificado.
CN121532510A (zh) *	2023-07-28	2026-02-13	苏州炫景生物科技有限公司	Cfb抑制剂组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY181251A (en) *	2013-09-13	2020-12-21	Ionis Pharmaceuticals Inc	Modulators of complement factor b
SG10201804960RA (en) *	2013-12-12	2018-07-30	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
EP3151839A4 (fr) *	2014-06-06	2018-02-28	Ionis Pharmaceuticals, Inc.	Compositions et méthodes assurant une meilleure absorption intestinale de composés oligomères conjugués

2017
- 2017-02-03 WO PCT/JP2017/003904 patent/WO2017135397A1/fr not_active Ceased
- 2017-02-03 TW TW106103617A patent/TW201730341A/zh unknown

Also Published As

Publication number	Publication date
WO2017135397A1 (fr)	2017-08-10

Publication	Publication Date	Title
TW201730341A (zh)	2017-09-01	抑制補體b因子之表現之反義寡核苷酸
US20170081667A1 (en)	2017-03-23	Nucleic acid that inhibits expression of irf5
TW201827596A (zh)	2018-08-01	抑制補體b因子之表現之核酸
EP3594345A1 (fr)	2020-01-15	Acide nucléique capable d'inhiber l'expression de masp2
EP4463553B1 (fr)	2025-10-01	Ciblage d'arn avancé (arnatar)
US11466272B2 (en)	2022-10-11	Nucleic acid suppressing expression of APCS
US20170247701A1 (en)	2017-08-31	Nucleic acid capable of inhibiting expression of beta-2gpi
CN113508175A (zh)	2021-10-15	用于治疗癌症的组合物和方法
CN115551519A (zh)	2022-12-30	用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN115698290A (zh)	2023-02-03	用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
WO2011074652A1 (fr)	2011-06-23	Acide nucléique capable d'inhiber l'expression de hif-2a
WO2025256564A1 (fr)	2025-12-18	Composition d'arni et son procédé d'utilisation
TW201713769A (zh)	2017-04-16	抑制β２ＧＰＩ之表現之反義寡核苷酸
HK40118739B (en)	2026-02-06	Advanced rna targeting (arnatar)
HK40118739A (en)	2025-06-27	Advanced rna targeting (arnatar)
CN120648679A (zh)	2025-09-16	抑制dmpk表达的多核苷酸分子及其用途
CN115605592A (zh)	2023-01-13	用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
HK40062991A (en)	2022-06-17	Compositions and methods for treating cancer